COVID-19-associated mucormycosis involving the maxilla

Mahboube Hasheminasab; Mojtaba Salehi Karizmeh; Reza Sharifi; Majid Beshkar; Narges Matloubi; Amir Ali Asadi; Elham Nazar

doi:10.1002/ccr3.6165

COVID-19-associated mucormycosis involving the maxilla

Clin Case Rep. 2022 Aug 3;10(8):e6165. doi: 10.1002/ccr3.6165. eCollection 2022 Aug.

Authors

Mahboube Hasheminasab¹, Mojtaba Salehi Karizmeh¹, Reza Sharifi¹, Majid Beshkar¹, Narges Matloubi¹, Amir Ali Asadi¹, Elham Nazar²

Affiliations

¹ Department of Oral and Maxillofacial Surgery and Craniomaxillofacial Research Center, Faculty of Dentistry Tehran University of Medical Sciences Tehran Iran.
² Department of Pathology Sina Hospital, Tehran University of Medical Sciences Tehran Iran.

Abstract

It is important to increase the awareness and knowledge of head and neck surgeons about the recent surge of craniofacial mucormycosis in COVID-19 patients because early diagnosis and appropriate treatment are essential to improve the outcomes. Here, we describe clinical features, treatment protocols, and outcomes of treatment in eight patients with COVID-19-associated mucormycosis in the maxilla. Consistent with the findings of previous studies, our experience in the management of these eight patients shows that early administration of amphotericin B and prompt aggressive surgery are essential for optimal control of the disease.

Keywords: COVID‐19; Mucormycosis; maxilla; pandemic.

Publication types

Case Reports